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TO THE EDITOR
Adenosine triphosphate (ATP) functions
as a chemical transmitter in almost
all types of cells, including skin cells
(Burnstock, 2007). Previously, we showed
that normal human epidermal keratino-
cytes (NHEKs) release ATP that mediates
inter-keratinocytic as well as keratino-
cyte-to-sensory communications via
P2Y2 receptors (Koizumi et al., 2004),
suggesting that ATP/P2 receptor-media-
ted signals in keratinocytes should be
important as both autocrine and parac-
rine signals in the skin. However, the
mechanism(s) underlying ATP release is
still a matter of debate. Recently, we iden-
tified SLC17A9 as a vesicular nucleotide
transporter (VNUT) that transports cyto-
solic ATP into vesicles (Sawada et al.,
2008). After this discovery, VNUT was
found to be essential for ATP exocytosis
in T cells (Tokunaga et al., 2010), neurons
(Larsson et al., 2012), and microglia
(Imura et al., 2013). As for skin cells, a
recent report showed that VNUT is
present in esophageal cells (Mihara
et al., 2011), but its function in epi-
dermal keratinocytes remained unknown.
First, NHEKs were stimulated with the
Ca2þ ionophore ionomycin for 20 min-
utes, and then the supernatant was col-
lected to measure the bulk release of ATP
from NHEKs. As shown in Supplemen-
tary Figure S1 online, the ionomycin-
evoked ATP release was dependent on
Ca2þ and vesicles. The pannexin/con-
nexin hemi-channel inhibitor, carbenox-
olone (at 10mM) had no effect on ATP
release (see caption of Supplementary
Figure S1 online). Thus, NHEKs appear
to release ATP by exocytosis.
Next, we tested the involvement of
VNUT in the ATP release. VNUT-posi-
tive signals were observed throughout
the epidermis, but were stronger in theAccepted article preview online 29 November 2013; published online 2 January 2014
Abbreviations: ATP, adenosine triphosphate; MANT-ATP, 20-/30-O-(N’-methylanthraniloyl) adenosine-50-
O-triphosphate, trisodium salt; MS, mechanical stimulation; NHEKs, normal human epidermal
keratinocytes; RFP, red fluorescent protein; VNUT, vesicular nucleotide transporter
K Inoue et al.
ATP Exocytosis in the Skin
www.jidonline.org 1465
granular cell layers, where they coloca-
lized with transglutaminase, a differentia-
tion marker of the skin (Figure 1a(i)). The
expression of VNUT protein in NHEKs
was confirmed by immunocytochemical
analysis (Figure 1a(ii)) and western blot
analysis (Figure 1a(iii)). When VNUT was
knocked down by VNUT siRNA#1
(Supplementary Figure S2 online), iono-
mycin-evoked ATP release was signifi-
cantly decreased (Figure 1b, also see
Supplementary Figure S3 online). These
results suggested that NHEKs release ATP
by VNUT-dependent exocytosis.
The ATP-containing vesicles and
VNUT-positive vesicles were simulta-
neously visualized by quinacrine and
VNUT-red fluorescent protein (RFP)
(Imura et al., 2013). Supplementary
Figure S4a online shows a typical image
of quinacrine (green) merged with
VNUT-RFP (red); the two signals were
colocalized. We also verified quina-
crine-positive signals in NHEKs using
20-/30-O-(N’-methylanthraniloyl) adeno-
sine-50-O-triphosphate, trisodium salt
(MANT-ATP), a fluorescent ATP, and
compared the localization of MANT-ATP
and VNUT-RFP signals. The majority of
quinacrine-positive and MANT-ATP
signals overlapped with VNUT-RFP
(Supplementary Figure S5a online).
Silencing of VNUT decreased the
intensity of MANT-ATP signals in
NHEKs (Supplementary Figure S5
online). These results indicate that
VNUT is responsible for the incorpora-
tion and concentration of ATP in the
VNUT-positive vesicles, and that quina-
crine could be used for imaging of ATP-
containing vesicles in NHEKs.
When stimulated with ionomycin, the
quinacrine signals in VNUT-positive vesi-
cles revealed burst-like behavior. The
sudden disappearance of individual vesi-
cles with different kinetics, which was
completely inhibited by BAPTA-AM, sug-
gested that these changes in quinacrine
fluorescence could reflect the exocytosis
of ATP in NHEKs (Supplementary Figure
S4b,c online). Such ATP exocytosis was
also observed when NHEKs were stimu-
lated with endogenous agonist ATP
(Supplementary Figure S6 online).
Previously, we showed that mechan-
ical stimulation (MS) of a single NHEK
resulted in the release of ATP and the
activation of P2Y2 receptors, leading to
the propagation of intercellular Ca2þ
waves in adjacent NHEKs by a mechan-
ism of ATP-induced ATP release (Koizumi
et al., 2004). When a single cell
(Figure 2a, cell 1) was gently stimulated
with a glass pipette, the quinacrine-fluo-
rescent signals showed a sudden decrease
with different kinetics (Figure 2b), which
was totally inhibited by BAPTA-AM
(Supplementary Figure S7 online), indicat-
ing that ATP exocytosis occurred in the
mechanically stimulated cell. The fre-
quencies of vesicular disappearance (exo-
cytosis) in the stimulated (cell 1) and
adjacent cells (cells 2 and 5) were plotted
against time. Cells 2 and 5 were located
53mm and 72mm from the stimulated cell
(cell 1), respectively (Figure 2c). The onset
of disappearance of the fluorescent vesi-
cles in cells 2 and 5 was slower than that
in the stimulated cell (cell 1; Figure 2b). In
addition, the delayed exocytosis in adja-
cent cells (such as cells 2 and 5) was
significantly inhibited by the P2 receptor
antagonist suramin, and the ATP-degrad-
ing enzyme apyrase (Supplementary
Figure S7 online), indicating that ATP
exocytosis in cells 2 and 5 was depen-
dent on ATP and P2 receptors.
There have been many reports on
non-exocytotic mechanisms of ATP
release in several types of cells, includ-
ing skin cells. For e.g., both volume-
regulated anion channel (Rugolo et al.,
1992) and cystic fibrosis transmembrane
conductance (Sato et al., 2002), which
are implicated in ATP efflux, are highly
expressed in human keratinocytes,
although direct evidence for the
involvement of these molecules in ATP
release is lacking. In this study, we
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Figure 1. Expression of vesicular nucleotide transporter (VNUT) and VNUT-dependent adenosine triphosphate (ATP) release. (a) (i) Immunohistochemical and
(ii) immunocytochemical staining of a frozen section of human skin and normal human epidermal keratinocytes (NHEKs), respectively, with VNUT-antibody.
(iii) VNUT section was co-stained with anti-transglutaminase and DAPI. (iii) For western blot analysis, the antibody that specifically recognizes VNUT protein
detected major bands at 65 kDa and 68 kDa. (b) Transfection with VNUT siRNA for 72 hours (n¼ 3, black bars) significantly decreased ionomycin-evoked ATP
release versus scrambled (scr) siRNA-transfection (white bars) at concentrations of 2 and 5mM ionomycin. ***Po0.001 vs. basal, ###Po0.001 vs. scr siRNA. Scale
bars¼200mm (a (i) VNUT), 50mm (a (i) high magnification), 10mm (a (ii)).
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found that ATP was exocytosed in
NHEKs. However, we recently showed
that Zn deficiency increases ATP release
by keratinocytes in response to irritant
chemicals; this release was not via
exocytosis (Kawamura et al., 2012).
Thus, keratinocytes have multiple path-
ways or mechanisms for ATP release that
would have distinct functions, presu-
mably depending on the kinds of stimuli
or conditions, including skin diseases.
Extracellular ATP has a role in trigger-
ing skin inflammation. Many studies
have shown that activation of P2 recep-
tors, such as P2X7 receptors, is highly
involved in pro-inflammatory responses
in human skin fibroblasts (Solini et al.,
1999), human dendritic cells (Ferrari
et al., 2000), a human dermal endo-
thelial cell line (Seiffert et al., 2006), and
human keratinocytes (Inoue et al.,
2007; Pastore et al., 2007). However,
we recently demonstrated that VNUT
mRNA and protein levels were increa-
sed by interleukin 1b-stimulated micro-
glia, and that these increases were
critical for triggering or amplifying
inflammation in the brain (Imura et al.,
2013). Thus, it is strongly suggested that
the functions and/or expression of
VNUT, in addition to P2 receptors,
may be a target for an anti-inflam-
matory response in skin cells.
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Figure 2. Mechanical stimulation (MS)-evoked ATP release and ATP-induced ATP release from NHEKs. (a) Quinacrine-labeled fluorescent and bright-field images
of NHEKs. Distance from MS cell (cell 1) is shown. (b) Left, typical quinacrine-labeled fluorescent images of cell 1, 2, and 5. Right upper: typical sequential images
of single quinacrine fluorescence (vesicle #1–#3, shown as squares in left panels) in response to MS. Right lower: time-course of MS-induced quinacrine-
quenching of individual vesicles (typical 2 vesicles) in time-lapse recording for the indicated period. Arrows show MS of cell 1. (c) Histogram of frequency of
exocytosis from individual vesicles of MS cell (cell 1) and adjacent cells (cells 2 and 5) over time. NHEKs, normal human epidermal keratinocytes.
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TO THE EDITOR
Vemurafenib, a BRAF-targeted therapy,
has revolutionized the treatment of
metastatic melanoma by showing highly
significant clinical objective responses
compared with those obtained hitherto
with standard treatments in patients
presenting a BRAFV600 mutation in
their tumor in a phase III clinical trial
(Flaherty et al., 2010; Chapman et al.,
2011). These mutations are found in
B50% of melanoma patients (Davies
et al., 2002). Since then, this new drug
has been approved in many countries
for the treatment of patients with unrese-
ctable or metastatic melanoma with a
BRAF mutation (BRAFV600E in the United
States, BRAFV600 in Europe). Therefore,
daily practice requires BRAF mutation
testing of patients’ tumors, in order to
start BRAF-inhibitor therapy. However,
it is not known whether primary
tumors and metastatic lesions can be
tested equivalently for BRAF mutations,
and there is no recommendation
on the number of samples to be tested
(Gonzalez et al., 2013). Further-
more, little data are available on
multiple melanoma sample testing in
the same patient.
We retrospectively determined the
BRAF mutation status of all samples
from consecutive inpatients with mela-
noma available in our unit between
January 2011 and June 2012. DNA
was extracted from paraffin-embedded
tumor blocks after highlighting tumor
areas by a pathologist and macrodissec-
tion. Detection of the most frequent
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Figure 1. Patients with several melanoma samples tested. (a) Patients with two samples tested for BRAF
mutation (n¼ 59), (b) patients with three samples tested for BRAF mutation (n¼15).
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